BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 12075714)

  • 1. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.
    Kengsakul K; Sathirapongsasuti K; Punyagupta S
    J Med Assoc Thai; 2002 Jan; 85(1):131-4. PubMed ID: 12075714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
    Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
    J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
    Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
    Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.
    Veit O; Niedrig M; Chapuis-Taillard C; Cavassini M; Mossdorf E; Schmid P; Bae HG; Litzba N; Staub T; Hatz C; Furrer H;
    Clin Infect Dis; 2009 Mar; 48(5):659-66. PubMed ID: 19191654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases.
    Receveur MC; Thiébaut R; Vedy S; Malvy D; Mercié P; Bras ML
    Clin Infect Dis; 2000 Sep; 31(3):E7-8. PubMed ID: 11017859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.
    Pistone T; Verdière CH; Receveur MC; Ezzedine K; Lafon ME; Malvy D
    Curr HIV Res; 2010 Sep; 8(6):461-6. PubMed ID: 20636276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow fever: epidemiology and prevention.
    Barnett ED
    Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of yellow fever in persons traveling to the tropics.
    Monath TP; Cetron MS
    Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Yellow fever vaccination: update on rare and severe adverse effects].
    Receveur MC; Bruyand M; Pistone T; Malvy D
    Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yellow fever vaccine for patients with HIV infection.
    Barte H; Horvath TH; Rutherford GW
    Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
    Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
    Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yellow fever - prevention in travellers.
    Neilson AA; Mayer CA
    Aust Fam Physician; 2010 Aug; 39(8):570-3. PubMed ID: 20877751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow Fever vaccine.
    Yax JA; Farnon EC; Cary Engleberg N
    J Travel Med; 2009; 16(5):365-7. PubMed ID: 19796110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute viscerotropic disease following vaccination against yellow fever.
    Hayes EB
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.